Thursday, 5 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call Transcript

Krishna Institute of Medical Sciences Earnings Call Transcript: Key Takeaways

KIMS delivered strong revenue growth led by Kondapur's rapid ramp-up, despite temporary margin compression from new oncology programs.

Krishna Institute Of Medical Sciences Q2 FY27 concall: date, live audio and summaryConcall page →
Highlights
Revenue growth41.3% YoY to ₹1,363 Cr, driven by Kondapur expansion.
MarginsTemporary dip due to new programs; long-term 25-30% target maintained.
Demand visibilityStrong IP/OP volumes indicate robust demand in core clusters.
Management confidenceHigh, emphasizing aggressive expansion and efficient hospital ramp-ups.

Growth

Consolidated revenue grew 41.3% YoY to ₹1,363 Cr, driven by volume and ARP growth.

Outlook

Expects 30% EBITDA margins at Kondapur and ₹1,100 Cr capex over next 18 months.

Risks

High fixed costs in expansion units and potential regulatory impact on anti-cancer drug margins.

Source

Earnings Call Transcript filed with NSE, NSE: KIMS. Summary written with AI assistance from the document.

Read the document ↗

Krishna Institute of Medical Sciences Ltd: key numbers

Share price
₹732.35
Market cap
₹30,759 Cr
Revenue (annual)
₹3,905 Cr
Net profit (annual)
₹241.4 Cr
P/E (TTM)
144.8×Sector 54.5×
Promoter holding
32.66%+0.16% QoQ
FII holding
15.01%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Krishna Institute of Medical Sciences Ltd

All →